1
|
Wishart DS, Kruger R, Sivakumaran A, Harford K, Sanford S, Doshi R, Khetarpal N, Fatokun O, Doucet D, Zubkowski A, Jackson H, Sykes G, Ramirez-Gaona M, Marcu A, Li C, Yee K, Garros C, Rayat D, Coleongco J, Nandyala T, Gautam V, Oler E. PathBank 2.0-the pathway database for model organism metabolomics. Nucleic Acids Res 2024; 52:D654-D662. [PMID: 37962386 PMCID: PMC10767802 DOI: 10.1093/nar/gkad1041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2023] [Revised: 10/19/2023] [Accepted: 10/31/2023] [Indexed: 11/15/2023] Open
Abstract
PathBank (https://pathbank.org) and its predecessor database, the Small Molecule Pathway Database (SMPDB), have been providing comprehensive metabolite pathway information for the metabolomics community since 2010. Over the past 14 years, these pathway databases have grown and evolved significantly to meet the needs of the metabolomics community and respond to continuing changes in computing technology. This year's update, PathBank 2.0, brings a number of important improvements and upgrades that should make the database more useful and more appealing to a larger cross-section of users. In particular, these improvements include: (i) a significant increase in the number of primary or canonical pathways (from 1720 to 6951); (ii) a massive increase in the total number of pathways (from 110 234 to 605 359); (iii) significant improvements to the quality of pathway diagrams and pathway descriptions; (iv) a strong emphasis on drug metabolism and drug mechanism pathways; (v) making most pathway images more slide-compatible and manuscript-compatible; (vi) adding tools to support better pathway filtering and selecting through a more complete pathway taxonomy; (vii) adding pathway analysis tools for visualizing and calculating pathway enrichment. Many other minor improvements and updates to the content, the interface and general performance of the PathBank website have also been made. Overall, we believe these upgrades and updates should greatly enhance PathBank's ease of use and its potential applications for interpreting metabolomics data.
Collapse
Affiliation(s)
- David S Wishart
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
- Department of Computing Science, University of Alberta, Edmonton, AB T6G 2E8, Canada
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G 2B7, Canada
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2H7, Canada
| | - Ray Kruger
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Aadhavya Sivakumaran
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Karxena Harford
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Selena Sanford
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Rahil Doshi
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Nitya Khetarpal
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Omolola Fatokun
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Daphnee Doucet
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Ashley Zubkowski
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Hayley Jackson
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Gina Sykes
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Miguel Ramirez-Gaona
- Department of Plant Breeding, Wageningen University and Research, 6708 PBWageningen, Gelderland, Netherlands
| | - Ana Marcu
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Carin Li
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Kristen Yee
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Christiana Garros
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Dorsa Yahya Rayat
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Jeanne Coleongco
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Tharuni Nandyala
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Vasuk Gautam
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Eponine Oler
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| |
Collapse
|
2
|
Knox C, Wilson M, Klinger C, Franklin M, Oler E, Wilson A, Pon A, Cox J, Chin NE, Strawbridge S, Garcia-Patino M, Kruger R, Sivakumaran A, Sanford S, Doshi R, Khetarpal N, Fatokun O, Doucet D, Zubkowski A, Rayat D, Jackson H, Harford K, Anjum A, Zakir M, Wang F, Tian S, Lee B, Liigand J, Peters H, Wang RQ, Nguyen T, So D, Sharp M, da Silva R, Gabriel C, Scantlebury J, Jasinski M, Ackerman D, Jewison T, Sajed T, Gautam V, Wishart D. DrugBank 6.0: the DrugBank Knowledgebase for 2024. Nucleic Acids Res 2024; 52:D1265-D1275. [PMID: 37953279 PMCID: PMC10767804 DOI: 10.1093/nar/gkad976] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2023] [Revised: 10/09/2023] [Accepted: 10/16/2023] [Indexed: 11/14/2023] Open
Abstract
First released in 2006, DrugBank (https://go.drugbank.com) has grown to become the 'gold standard' knowledge resource for drug, drug-target and related pharmaceutical information. DrugBank is widely used across many diverse biomedical research and clinical applications, and averages more than 30 million views/year. Since its last update in 2018, we have been actively enhancing the quantity and quality of the drug data in this knowledgebase. In this latest release (DrugBank 6.0), the number of FDA approved drugs has grown from 2646 to 4563 (a 72% increase), the number of investigational drugs has grown from 3394 to 6231 (a 38% increase), the number of drug-drug interactions increased from 365 984 to 1 413 413 (a 300% increase), and the number of drug-food interactions expanded from 1195 to 2475 (a 200% increase). In addition to this notable expansion in database size, we have added thousands of new, colorful, richly annotated pathways depicting drug mechanisms and drug metabolism. Likewise, existing datasets have been significantly improved and expanded, by adding more information on drug indications, drug-drug interactions, drug-food interactions and many other relevant data types for 11 891 drugs. We have also added experimental and predicted MS/MS spectra, 1D/2D-NMR spectra, CCS (collision cross section), RT (retention time) and RI (retention index) data for 9464 of DrugBank's 11 710 small molecule drugs. These and other improvements should make DrugBank 6.0 even more useful to a much wider research audience ranging from medicinal chemists to metabolomics specialists to pharmacologists.
Collapse
Affiliation(s)
- Craig Knox
- OMx Personal Health Analytics, Inc., 700–10130 103 St NW, Edmonton, AB T5J 1B9, Canada
| | - Mike Wilson
- OMx Personal Health Analytics, Inc., 700–10130 103 St NW, Edmonton, AB T5J 1B9, Canada
| | - Christen M Klinger
- OMx Personal Health Analytics, Inc., 700–10130 103 St NW, Edmonton, AB T5J 1B9, Canada
| | - Mark Franklin
- OMx Personal Health Analytics, Inc., 700–10130 103 St NW, Edmonton, AB T5J 1B9, Canada
| | - Eponine Oler
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Alex Wilson
- OMx Personal Health Analytics, Inc., 700–10130 103 St NW, Edmonton, AB T5J 1B9, Canada
| | - Allison Pon
- OMx Personal Health Analytics, Inc., 700–10130 103 St NW, Edmonton, AB T5J 1B9, Canada
| | - Jordan Cox
- OMx Personal Health Analytics, Inc., 700–10130 103 St NW, Edmonton, AB T5J 1B9, Canada
| | - Na Eun (Lucy) Chin
- OMx Personal Health Analytics, Inc., 700–10130 103 St NW, Edmonton, AB T5J 1B9, Canada
| | - Seth A Strawbridge
- OMx Personal Health Analytics, Inc., 700–10130 103 St NW, Edmonton, AB T5J 1B9, Canada
| | - Marysol Garcia-Patino
- OMx Personal Health Analytics, Inc., 700–10130 103 St NW, Edmonton, AB T5J 1B9, Canada
| | - Ray Kruger
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Aadhavya Sivakumaran
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Selena Sanford
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Rahil Doshi
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Nitya Khetarpal
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Omolola Fatokun
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Daphnee Doucet
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Ashley Zubkowski
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Dorsa Yahya Rayat
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Hayley Jackson
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Karxena Harford
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Afia Anjum
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Mahi Zakir
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Fei Wang
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Siyang Tian
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Brian Lee
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Jaanus Liigand
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
- Institute of Chemistry, University of Tartu, Tartu, Estonia
| | - Harrison Peters
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Ruo Qi (Rachel) Wang
- OMx Personal Health Analytics, Inc., 700–10130 103 St NW, Edmonton, AB T5J 1B9, Canada
| | - Tue Nguyen
- OMx Personal Health Analytics, Inc., 700–10130 103 St NW, Edmonton, AB T5J 1B9, Canada
| | - Denise So
- OMx Personal Health Analytics, Inc., 700–10130 103 St NW, Edmonton, AB T5J 1B9, Canada
| | - Matthew Sharp
- OMx Personal Health Analytics, Inc., 700–10130 103 St NW, Edmonton, AB T5J 1B9, Canada
| | - Rodolfo da Silva
- OMx Personal Health Analytics, Inc., 700–10130 103 St NW, Edmonton, AB T5J 1B9, Canada
| | - Cyrella Gabriel
- OMx Personal Health Analytics, Inc., 700–10130 103 St NW, Edmonton, AB T5J 1B9, Canada
| | - Joshua Scantlebury
- OMx Personal Health Analytics, Inc., 700–10130 103 St NW, Edmonton, AB T5J 1B9, Canada
| | - Marissa Jasinski
- OMx Personal Health Analytics, Inc., 700–10130 103 St NW, Edmonton, AB T5J 1B9, Canada
| | - David Ackerman
- OMx Personal Health Analytics, Inc., 700–10130 103 St NW, Edmonton, AB T5J 1B9, Canada
| | - Timothy Jewison
- OMx Personal Health Analytics, Inc., 700–10130 103 St NW, Edmonton, AB T5J 1B9, Canada
| | - Tanvir Sajed
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - Vasuk Gautam
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
| | - David S Wishart
- Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada
- Department of Computing Science, University of Alberta, Edmonton, AB T6G 2E8, Canada
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2H1, Canada
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G 1C9, Canada
| |
Collapse
|
3
|
Jackson H, Bowen S, Jaki T. Using biomarkers to allocate patients in a response-adaptive clinical trial. COMMUN STAT-SIMUL C 2023; 52:5946-5965. [PMID: 38045870 PMCID: PMC7615340 DOI: 10.1080/03610918.2021.2004420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Accepted: 11/05/2021] [Indexed: 10/19/2022]
Abstract
In this paper, we discuss a response adaptive randomization method, and why it should be used in clinical trials for rare diseases compared to a randomized controlled trial with equal fixed randomization. The developed method uses a patient's biomarkers to alter the allocation probability to each treatment, in order to emphasize the benefit to the trial population. The method starts with an initial burn-in period of a small number of patients, who with equal probability, are allocated to each treatment. We then use a regression method to predict the best outcome of the next patient, using their biomarkers and the information from the previous patients. This estimated best treatment is assigned to the next patient with high probability. A completed clinical trial for the effect of catumaxomab on the survival of cancer patients is used as an example to demonstrate the use of the method and the differences to a controlled trial with equal allocation. Different regression procedures are investigated and compared to a randomized controlled trial, using efficacy and ethical measures.
Collapse
Affiliation(s)
| | | | - T Jaki
- Lancaster University, Lancaster, UK
- University of Cambridge, Cambridge, UK
| |
Collapse
|
4
|
Aleman A, van Kesteren M, Zajdman AK, Srivastava K, Cognigni C, Mischka J, Chen LY, Upadhyaya B, Serebryakova K, Nardulli JR, Lyttle N, Kappes K, Jackson H, Gleason CR, Oostenink A, Cai GY, Van Oekelen O, van Bakel H, Sordillo EM, Cordon-Cardo C, Merad M, Jagannath S, Wajnberg A, Simon V, Parekh S. Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma. EBioMedicine 2023; 98:104886. [PMID: 37995467 PMCID: PMC10708991 DOI: 10.1016/j.ebiom.2023.104886] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2023] [Revised: 11/06/2023] [Accepted: 11/08/2023] [Indexed: 11/25/2023] Open
Abstract
BACKGROUND The real-world impact of bivalent vaccines for wild type (WA.1) and Omicron variant (BA.5) is largely unknown in immunocompromised patients with Multiple Myeloma (MM). We characterize the humoral and cellular immune responses in patients with MM before and after receiving the bivalent booster, including neutralizing assays to identify patterns associated with continuing vulnerability to current variants (XBB1.16, EG5) in the current post-pandemic era. METHODS We studied the humoral and cellular immune responses before and after bivalent booster immunization in 48 MM patients. Spike binding IgG antibody levels were measured by SARS-CoV-2 spike binding ELISA and neutralization capacity was assessed by a SARS-CoV-2 multi-cycle microneutralization assays to assess inhibition of live virus. We measured spike specific T-cell function using the QuantiFERON SARS-CoV-2 (Qiagen) assay as well as flow-cytometry based T-cell. In a subset of 38 patients, high-dimensional flow cytometry was performed to identify immune cell subsets associated with lack of humoral antibodies. FINDINGS We find that bivalent vaccination provides significant boost in protection to the omicron variant in our MM patients, in a treatment specific manner. MM patients remain vulnerable to newer variants with mutations in the spike portion. Anti-CD38 and anti-BCMA therapies affect the immune machinery needed to produce antibodies. INTERPRETATION Our study highlights varying immune responses observed in MM patients after receiving bivalent COVID-19 vaccination. Specifically, a subgroup of MM patients undergoing anti-CD38 and anti-BCMA therapy experience impairment in immune cells such DCs, B cells, NK cells and TFH cells, leading to an inability to generate adequate humoral and cellular responses to vaccination. FUNDING National Cancer Institute (National Institutes of Health), National Institute of Allergy and Infectious Diseases (National Institutes of Health), NCI Serological Sciences Network for COVID-19 (SeroNet) and The Icahn School of Medicine at Mount Sinai.
Collapse
Affiliation(s)
- Adolfo Aleman
- Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Morgan van Kesteren
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Ariel Kogan Zajdman
- Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Komal Srivastava
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Christian Cognigni
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Jacob Mischka
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Lucia Y Chen
- Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Bhaskar Upadhyaya
- Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Kseniya Serebryakova
- Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Jessica R Nardulli
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Neko Lyttle
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Katerina Kappes
- Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Hayley Jackson
- Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Charles R Gleason
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Annika Oostenink
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Gianna Y Cai
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Oliver Van Oekelen
- Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Harm van Bakel
- Department of Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, NY, USA
| | - Emilia Mia Sordillo
- Department of Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Carlos Cordon-Cardo
- Department of Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, NY, USA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Miriam Merad
- Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Sundar Jagannath
- Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Ania Wajnberg
- Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, NY, USA
| | - Viviana Simon
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Division of Infectious Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Global Health and Emerging Pathogen Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
| | - Samir Parekh
- Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
| |
Collapse
|
5
|
Jackson H, MacBride C, Taylor L, Carey M, Higgins MF. Patients' attitudes to bedside teaching after the COVID-19 pandemic. Ir J Med Sci 2023:10.1007/s11845-023-03558-5. [PMID: 37917306 DOI: 10.1007/s11845-023-03558-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2023] [Accepted: 10/24/2023] [Indexed: 11/04/2023]
Abstract
BACKGROUND Bedside teaching (BST) is a method of structured clinical teaching where the patient is central in education. We had previously explored the patients' perceptions of BST using both a qualitative research study and validation of a questionnaire, both showing strong support by patients for BST once basic rules of respect and confidentiality are followed. With the COVID-19 pandemic, clinical education transitioned to online/virtual learning. AIM The aim of this study was to explore patients' attitudes towards reintroduction of BST as the pandemic restrictions have lifted. METHODS Patients were invited to complete a validated questionnaire exploring their attitudes towards BST. A descriptive analysis was performed. Results were compared to a previous study performed before the COVID-19 pandemic. RESULTS Four hundred patients consented to complete the questionnaires. Participants included women attending for antenatal (40%), postnatal (33%) and gynaecology issues (28%). Most patients (> 94%) reported that they were happy to be involved in BST. Patients believed that they should not be asked to participate in BST should they feel stressed or unwell (69%). These findings were the same as our previous study, performed prior to the pandemic. CONCLUSION This study shows extensive and persisting patient support for BST. BST is unique in that it allows students to gain a deeper understanding of the disease which are hard to elicit through online/virtual methods.
Collapse
Affiliation(s)
- Hayley Jackson
- UCD School of Medicine, University College Dublin, Dublin, Ireland
| | - Claire MacBride
- UCD School of Medicine, University College Dublin, Dublin, Ireland
| | - Laura Taylor
- UCD School of Psychology, University College Dublin, Dublin, Ireland
| | - Michael Carey
- UCD Perinatal Research Centre, Obstetrics and Gynaecology, National Maternity Hospital, Dublin, Ireland
| | - Mary F Higgins
- UCD School of Medicine, University College Dublin, Dublin, Ireland.
- UCD Perinatal Research Centre, Obstetrics and Gynaecology, National Maternity Hospital, Dublin, Ireland.
| |
Collapse
|
6
|
Cartwright M, Louw-du Toit R, Jackson H, Janse van Vuuren M, Africander D. Progesterone receptor isoform ratios influence the transcriptional activity of progestins via the progesterone receptor. J Steroid Biochem Mol Biol 2023; 232:106348. [PMID: 37315868 DOI: 10.1016/j.jsbmb.2023.106348] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Revised: 06/07/2023] [Accepted: 06/09/2023] [Indexed: 06/16/2023]
Abstract
Progestins (synthetic progestogens) are progesterone receptor (PR) ligands used globally by women in both hormonal contraception and menopausal hormone therapy. Although four generations of unique progestins have been developed, studies seldom distinguish between the activities of progestins via the two functionally distinct PR isoforms, PR-A and PR-B. Moreover, not much is known about the action of progestins in breast cancer tumors where PR-A is mostly overexpressed relative to PR-B. Understanding progestin action in breast cancer is crucial since the clinical use of some progestins has been associated with an increased risk of developing breast cancer. This study directly compared the agonist activities of selected progestins from all four generations for transactivation and transrepression via either PR-A or PR-B, and when PR-A and PR-B were co-expressed at ratios comparable to those detected in breast cancer tumors. Comparative dose-response analysis showed that earlier generation progestins mostly displayed similar efficacies for transactivation on a minimal progesterone response element via the PR isoforms, while most of the 4th generation progestins, similar to the natural progestogen, progesterone (P4), were more efficacious via PR-B. Most of the progestogens were however more potent via PR-A. We are the first to show that the efficacies of the selected progestogens via the individual PR isoforms were generally decreased when PR-A and PR-B were co-expressed, irrespective of the ratio of PR-A:PR-B. While the potencies of most progestogens via PR-B were enhanced when the ratio of PR-A relative to PR-B was increased, those via PR-A were minimally influenced. This study is also the first to report that all progestogens evaluated, except 1st generation medroxyprogesterone acetate and 4th generation drospirenone, displayed similar agonist activity for transrepression via PR-A and PR-B on a minimal nuclear factor kappa B containing promoter. Moreover, we showed that the progestogen activity for transrepression was significantly increased when PR-A and PR-B were co-expressed. Taken together, our results highlight that PR agonists (progestogens) do not always display the same activity via PR-A and PR-B, or when PR-A and PR-B are co-expressed at ratios mimicking those found in breast cancer tumors. These results suggest that biological responses are progestogen- and PR isoform-dependent and may differ in target tissues expressing varying PR-A:PR-B ratios.
Collapse
Affiliation(s)
- Meghan Cartwright
- Department of Biochemistry, Stellenbosch University, Private Bag X1, Matieland 7602, South Africa.
| | - Renate Louw-du Toit
- Department of Biochemistry, Stellenbosch University, Private Bag X1, Matieland 7602, South Africa.
| | - Hayley Jackson
- Department of Biochemistry, Stellenbosch University, Private Bag X1, Matieland 7602, South Africa.
| | - Melani Janse van Vuuren
- Department of Biochemistry, Stellenbosch University, Private Bag X1, Matieland 7602, South Africa.
| | - Donita Africander
- Department of Biochemistry, Stellenbosch University, Private Bag X1, Matieland 7602, South Africa.
| |
Collapse
|
7
|
Jackson H, Mann G, Martini A, Troeung L, Beros K, Prinsloo A. Change in care hours, cost, and functional independence following continence and assistive technology intervention in an acquired brain injury population. Disabil Rehabil 2023; 45:1208-1219. [PMID: 35442857 DOI: 10.1080/09638288.2022.2055169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
PURPOSE After acquired brain injury (ABI) dependence on intervention for continence management is common. This preliminary investigation aimed to (i) quantify toileting care hours and costs in a community-based ABI rehabilitation and disability setting, and (ii) measure change in care needs, costs, and functional independence after intervention with assistive technologies (ATs). METHOD Pragmatic pre-post intervention pilot study of 14 adults with ABI and toileting disability accessing community-based neurorehabilitation or disability support in Western Australia. Toileting and functional independence were assessed monthly from baseline (T0) to 3-month follow-up (T3). Basic and nursing care hours (Northwick Park Dependency Score), cost of care estimates (Northwick Park Care Needs Assessment), functional independence (Functional Independence and Assessment Measure), and cost of consumables were examined pre- and post-intervention with ATs. Multilevel mixed-effects models with bootstrap estimation were conducted. RESULTS Cost of consumables significantly declined (AU$69/week), and functional independence significantly improved following intervention (+23.5 points). There was a non-significant reduction in care needs for toileting (4 h/week) and in the cost of toileting care (AU$633/week). CONCLUSION Toileting disability substantially impacts care hours and costs. This study provides preliminary evidence that comprehensive continence management is beneficial in reducing costs and supporting people with an ABI to increase their independence.IMPLICATIONS FOR REHABILITATIONA comprehensive continence assessment and management plan reduces the number of care hours, cost of care, and cost of continence products in a neurorehabilitation and disability support sample for people with acquired brain injury (ABI).Assistive technologies for continence management are beneficial in supporting people with ABI to increase independence, and reduce costs.Providing comprehensive continence assessment and management plan reduces reliance on staff for continence care, and improves functional independence.
Collapse
Affiliation(s)
- Hayley Jackson
- Brightwater Care Group, Brightwater Research Centre, Perth, Australia
| | - Georgina Mann
- Brightwater Care Group, Brightwater Research Centre, Perth, Australia
| | - Angelita Martini
- Brightwater Care Group, Brightwater Research Centre, Perth, Australia
| | - Lakkhina Troeung
- Brightwater Care Group, Brightwater Research Centre, Perth, Australia
| | - Katie Beros
- Brightwater Care Group, Brightwater Research Centre, Perth, Australia
| | - Annelize Prinsloo
- Brightwater Care Group, Brightwater Research Centre, Perth, Australia
| |
Collapse
|
8
|
Perkins MS, Louw-du Toit R, Jackson H, Simons M, Africander D. Upregulation of an estrogen receptor-regulated gene by first generation progestins requires both the progesterone receptor and estrogen receptor alpha. Front Endocrinol (Lausanne) 2022; 13:959396. [PMID: 36187129 PMCID: PMC9519895 DOI: 10.3389/fendo.2022.959396] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/02/2022] [Accepted: 08/30/2022] [Indexed: 11/13/2022] Open
Abstract
Progestins, synthetic compounds designed to mimic the activity of natural progesterone (P4), are used globally in menopausal hormone therapy. Although the older progestins medroxyprogesterone acetate (MPA) and norethisterone (NET) have been implicated in increased breast cancer risk, little is known regarding newer progestins, and no significant risk has been associated with P4. Considering that breast cancer is the leading cause of mortality in women, establishing which progestins increase breast cancer incidence and elucidating the underlying mechanisms is a global priority. We showed for the first time that the newer-generation progestin drospirenone (DRSP) is the least potent progestin in terms of proliferation of the estrogen-responsive MCF-7 BUS breast cancer cell line, while NET and P4 have similar potencies to estradiol (E2), the known driver of breast cancer cell proliferation. Notably, MPA, the progestin most frequently associated with increased breast cancer risk, was significantly more potent than E2. While all the progestogens enhanced the anchorage-independent growth of the MCF-7 BUS cell line, MPA promoted a greater number of colonies than P4, NET or DRSP. None of the progestogens inhibited E2-induced proliferation and anchorage-independent growth. We also showed that under non-estrogenic conditions, MPA and NET, unlike P4 and DRSP, increased the expression of the estrogen receptor (ER) target gene, cathepsin D, via a mechanism requiring the co-recruitment of ERα and the progesterone receptor (PR) to the promoter region. In contrast, all progestogens promoted the association of the PR and ERα on the promoter of the PR target gene, MYC, thereby increasing its expression under non-estrogenic and estrogenic conditions. These results suggest that progestins differentially regulate the way the PR and ER converge to modulate the expression of PR and ER-regulated genes. Our novel findings indicating similarities and differences between P4 and the progestins, emphasize the importance of comparatively investigating effects of individual progestins rather than grouping them as a class. Further studies are required to underpin the clinical relevance of PR/ERα crosstalk in response to different progestins in both normal and malignant breast tissue, to either confirm or refute their suitability in combination therapy for ER-positive breast cancer.
Collapse
Affiliation(s)
| | | | | | | | - Donita Africander
- Department of Biochemistry, Stellenbosch University, Stellenbosch, South Africa
| |
Collapse
|
9
|
Gomez A, Capon-Saez A, Gomez-Mosquera A, Parada-DeFreitas Y, Arechaderra-Calderon JJ, Hoyos E, Jackson H, Ramon-Espinoza F, Vilches-Moraga A. 433 SAME SPECIALITY, DIFFERENT REALITY? Age Ageing 2021. [DOI: 10.1093/ageing/afab119.03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
The United Kingdom and Spain run government-funded social and health care services, free for the user at the point of delivery. Acute Geriatric Units (AGU) carrying out Comprehensive Geriatric Assessments improve the clinical outcomes of older patients. Little is known about the similarities and differences between countries, and how these may impact on clinical outcomes.
Methods
Prospective observational study of consecutive patients admitted to AGU of 2 hospitals in the UK and 4 hospitals in Spain between the 1st to the 30th of October 2019 and from the 1st to the 29th of February 2020. We followed up the patients for a 90 day period.
Conclusions
Frailty, multimorbidity and polypharmacy were prevalent in both cohorts. English patients were younger, with shorter hospital stay, mortality and use of antipsychotic medication but higher readmission rates. Involvement from Allied health care professionals was higher in UK hospitals.
Collapse
Affiliation(s)
| | | | | | | | | | - E Hoyos
- Salford Royal NHS Foundation Trust
| | | | | | | |
Collapse
|
10
|
Backes KM, Palken DA, Kenany SA, Brubaker BM, Cahn SB, Droster A, Hilton GC, Ghosh S, Jackson H, Lamoreaux SK, Leder AF, Lehnert KW, Lewis SM, Malnou M, Maruyama RH, Rapidis NM, Simanovskaia M, Singh S, Speller DH, Urdinaran I, Vale LR, van Assendelft EC, van Bibber K, Wang H. A quantum enhanced search for dark matter axions. Nature 2021; 590:238-242. [DOI: 10.1038/s41586-021-03226-7] [Citation(s) in RCA: 92] [Impact Index Per Article: 30.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2020] [Accepted: 12/08/2020] [Indexed: 11/09/2022]
|
11
|
Williams E, Jackson H, Wagland J, Martini A. Community Rehabilitation Outcomes for Different Stroke Diagnoses: An Observational Cohort Study. Arch Rehabil Res Clin Transl 2021; 2:100047. [PMID: 33543075 PMCID: PMC7853334 DOI: 10.1016/j.arrct.2020.100047] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Objective To determine the differences in functional and cognitive rehabilitation gains made in community-based rehabilitation following a stroke based on stroke diagnosis (left or right hemisphere, hemorrhagic, or ischemic). Design A 12-month follow-up observational retrospective cohort study. Setting Staged community-based brain injury rehabilitation. Participants Clients (N=61) with hemorrhagic left brain stroke (n=10), hemorrhagic right brain stroke (n=8), ischemic left brain stroke (n=27), or ischemic right brain stroke (n=16) participating in rehabilitation for at least 12 months. Intervention Not applicable. Main Outcome Measures The Mayo-Portland Adaptability Inventory-4 (MPAI-4) was completed at admission and 12 months post admission to staged community-based brain injury rehabilitation by consensus of a multidisciplinary team. Results After 12 months in staged community-based brain injury rehabilitation, the study population made significant gains in Total (P<.001) and across Ability (P<.001) and Participation (P<.001) subscales of the MPAI-4. All diagnostic groups made significant gains in Participation T-scores, and no groups made significant gains in Adjustment. The ischemic left and right hemisphere stroke groups also made significant gains in Ability and Total T-scores from admission to 12 months. Clients with ischemic left hemisphere stroke had more severe limitations in motor speech (P<.05) than clients with right hemisphere stroke at admission and/or review and were also more impaired in verbal communication (P<.01) than the hemorrhagic right hemisphere group at admission. Conclusions There are some differences in outcomes on presentation to rehabilitation based on type of stroke; there are also differences in rehabilitation gains. Improvement in physical ability does not always translate to improvement in social participation and independence; those with right brain stroke need further assistance to translate physical gains into participatory outcomes.
Collapse
Affiliation(s)
- Elly Williams
- Brightwater Care Group, Research Centre, Perth, Australia
| | - Hayley Jackson
- Brightwater Care Group, Research Centre, Perth, Australia.,University of Western Australia, Faculty of Science, School of Psychological Science, Perth, Australia
| | - Janet Wagland
- Brightwater Care Group, Research Centre, Perth, Australia
| | | |
Collapse
|
12
|
Williams E, Martini A, Jackson H, Wagland J, Turner-Stokes L. Time between acquired brain injury and admission to community-based rehabilitation: differences in cognitive and functional gains. Brain Inj 2020; 34:713-722. [PMID: 32255368 DOI: 10.1080/02699052.2020.1740943] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
OBJECTIVE To determine differences in rehabilitation gains made by people with an acquired brain injury undergoing staged community-based brain injury rehabilitation (SCBIR) at different times between injury and admission. METHOD Retrospective cohort analysis of routinely collected demographic and rehabilitation data from clients admitted to SCBIR service 2011-2017 (n=92). Outcome measures: Mayo-Portland Adaptability Inventory-4 (MPAI-4) and UK Functional Assessment Measure (UK FIM+FAM) collected on admission and annually thereafter until discharge. Analysis was stratified by time since injury on admission: 'Early' (<1 year (n=36)), 'Middle' (1-2 years (n=34)) and 'Late' (>2 years (n=22)). Between-group differences were tested using bootstrapped one-way ANOVA. Within-group differences were tested using paired T tests. RESULTS Total cohort made significant gains in MPAI-4 and UK FIM+FAM total and all subscales (p = .001). Early group made greatest change in all subscales of both outcome measures (p < .01). Middle cohort improved significantly in all subscales (p < .02) excluding MPAI-4 Adjustment. Late cohort still made statistically significant gains in all UK FIM+FAM subscales (p < .05) and MPAI-4 Participation (p < .01). Item level changes are presented. CONCLUSION More than 2 years after injury, people are able to make improvements in participation and functional independence following SCBIR.
Collapse
Affiliation(s)
- Elly Williams
- Brightwater Research Centre, Brightwater Care Group , Perth, Australia
| | - Angelita Martini
- Brightwater Research Centre, Brightwater Care Group , Perth, Australia
| | - Hayley Jackson
- Brightwater Research Centre, Brightwater Care Group , Perth, Australia.,School of Psychological Science, University of Western Australia , Perth, Australia
| | - Janet Wagland
- Brightwater Research Centre, Brightwater Care Group , Perth, Australia.,Brightwater Care Group , Perth, Australia
| | - Lynne Turner-Stokes
- Department of Palliative Care, Policy and Rehabilitation, Cicely Saunders Institute, King's College London , London, UK.,Regional Hyper-acute Rehabilitation Unit, Northwick Park Hospital, London North West Healthcare NHS Trust , London, UK
| |
Collapse
|
13
|
Bird CB, Malone B, Rice LG, Ross PF, Eppley R, Abouzied MM, Ashman P, Carpenter N, Drouches M, Fairchild A, Hartman R, Herald S, Holloway S, Horrisberger G, Jackson H, Jones K, Landis K, Leichtweis H, Peden J. Determination of Total Fumonisins in Corn by Competitive Direct Enzyme-Linked Immunosorbent Assay: Collaborative Study. J AOAC Int 2019. [DOI: 10.1093/jaoac/85.2.404] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Fumonisins—mycotoxins produced by some Fusarium species—have been shown to be the causative agent of diseases in horses and other domesticated animals as well as possible carcinogens in humans. A collaborative study was conducted to evaluate the effectiveness of a competitive direct enzyme-linked immunosorbent assay (CD-ELISA) for the determination of total fumonisins (B1, B2, and B3) in corn. The test portion was extracted with methanol–water (7 + 3), filtered, diluted, and tested on the CD-ELISA. Naturally and artificially contaminated corn test portions were sent to 13 collaborators in the United States. Naturally contaminated field test portions were prepared at 3 different levels. Artificially contaminated test portions were spiked at 1.0, 3.0, and 5.0 mg/kg total fumonisins (B1, B2, and B3). Average recoveries of total fumonisins were 120, 100, and 90%, respectively. The relative standard deviations for repeatability ranged from 13.3 to 23.3% and the relative standard deviations for reproducibility ranged from 15.8 to 30.3% across all levels tested. HORRAT values, calculated for each individual sample, ranged from 1.24 to 1.94. This method demonstrated acceptable intra- and interlaboratory precision at the levels tested.
Collapse
Affiliation(s)
| | - Bruce Malone
- Trilogy Analytical Laboratory, Inc., 111 W. Fourth St, Washington, MO 63090
| | - Larry G Rice
- U.S. Department of Agriculture, Animal and Plant Health Inspection Service, National Veterinary Services Laboratory, 1800 Dayton Rd, Ames, IA 50010
| | - P Frank Ross
- U.S. Department of Agriculture, Animal and Plant Health Inspection Service, National Veterinary Services Laboratory, 1800 Dayton Rd, Ames, IA 50010
| | - Robert Eppley
- U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, 200 C St, SW, Washington, DC 20204
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Rothwell L, Jackson H, Engel B. The effectiveness of hand grip dynamometry in assessing the nutritional status of renal inpatients. Clin Nutr ESPEN 2019. [DOI: 10.1016/j.clnesp.2018.12.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
15
|
Jackson H, Bhattacharya S, Bojczuk P, Kilian D, Seestaller Wehr L, Hahn A, Shi H, Bi M, Adam M, Jing J, Morley P, Hopson C, Paul E, Hoos A, Smothers J, Srinivasan R, Yanamandra N. Evaluation of OX40 receptor density, influence of IgG Isotype and dosing paradigm in anti-OX40-mediated efficacy and biomarker responses with PD-1 blockade. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Brett S, Yadavilli S, Seestaller-Wehr L, Bhattacharya S, Jackson H, Bi M, Willoughby J, Zhang T, Liu YB, Katlinskaya Y, Shi H, Jing J, Hahn A, Speller S, David Figueroa D, Yu J, Olive D, Cragg M, Mayes P, Hoos A. Preclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy303.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
17
|
Byrne M, Symington M, Stainer B, Leighton J, Jackson H, Singhal N, Shiel-Rankin S, Mayes J, Mogg J, Bonham T, Smit A, Deutsch B, Wilson C. School Level Education to Increase Organ Donation and The Effect Of Deprivation. Int J Surg 2018. [DOI: 10.1016/j.ijsu.2018.05.695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
18
|
Byrne M, Jackson H, Sinha A, Tong G, Grafton-Clarke C, Rees S, Mathur A, Cross B, Christopher E, Isaacs L, Banh S, Sheng Z, Lundin R. The National Student Association of Medical Research (NSAMR) Publication Pathway. Int J Surg 2017. [DOI: 10.1016/j.ijsu.2017.08.287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
Pali‐Schöll I, De Lucia M, Jackson H, Janda J, Mueller RS, Jensen‐Jarolim E. Comparing immediate-type food allergy in humans and companion animals-revealing unmet needs. Allergy 2017; 72:1643-1656. [PMID: 28394404 DOI: 10.1111/all.13179] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/05/2017] [Indexed: 12/15/2022]
Abstract
Adverse food reactions occur in human as well as veterinary patients. Systematic comparison may lead to improved recommendations for prevention and treatment in both. In this position paper, we summarize the current knowledge on immediate-type food allergy vs other food adverse reactions in companion animals, and compare this to the human situation. While the prevalence of food allergy in humans has been well studied for some allergens, this remains to be investigated for animal patients, where owner-reported as well as veterinarian-diagnosed food adverse reactions are on the increase. The characteristics of the disease in humans vs dogs, cats, and horses are most often caused by similar, but sometimes species-dependent different pathophysiological mechanisms, prompting the specific clinical symptoms, diagnoses, and treatments. Furthermore, little is known about the allergen molecules causative for type I food allergy in animals, which, like in human patients, could represent predictive biomarkers for risk evaluation. The definite diagnosis of food allergy relies-as in humans-on elimination diet and provocation tests. Besides allergen avoidance in daily practice, novel treatment options and tolerization strategies are underway. Taken together, numerous knowledge gaps were identified in veterinary food allergy, which need to be filled by systematic comparative studies.
Collapse
Affiliation(s)
- I. Pali‐Schöll
- Comparative Medicine The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna Medical University of Vienna and University of Vienna Vienna Austria
| | - M. De Lucia
- Clinica Veterinaria Privata San Marco Padova Italy
| | - H. Jackson
- Dermatology Referral Services LTD Glasgow Scotland UK
| | - J. Janda
- Faculty of Science Charles University Prague Czech Republic
| | - R. S. Mueller
- Centre for Clinical Veterinary Medicine Ludwig Maximilian University Munich Munich Germany
| | - E. Jensen‐Jarolim
- Comparative Medicine The Interuniversity Messerli Research Institute of the University of Veterinary Medicine Vienna Medical University of Vienna and University of Vienna Vienna Austria
- Institute of Pathophysiology and Allergy Research Center of Pathophysiology Infectiology and Immunology Medical University of Vienna Vienna Austria
- Allergy Care Allergy Diagnosis and Study Center Vienna Austria
| |
Collapse
|
20
|
Forman J, Jackson H, Walter C, Hawkins N, Krahn A, Bashir J. THE SUBCUTANEOUS IMPLANTABLE CARDIOVERTER DEFIBRILLATOR EXPERIENCE IN BRITISH COLUMBIA – PROVINCIAL COORDINATION ENABLES DISTRIBUTED PATIENT ACCESS TO NEW TECHNOLOGY. Can J Cardiol 2017. [DOI: 10.1016/j.cjca.2017.07.160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
21
|
Jackson H, MacLeod AK. Well-being in Chronic Fatigue Syndrome: Relationship to Symptoms and Psychological Distress. Clin Psychol Psychother 2016; 24:859-869. [DOI: 10.1002/cpp.2051] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2016] [Revised: 09/23/2016] [Accepted: 09/27/2016] [Indexed: 01/30/2023]
Affiliation(s)
- H. Jackson
- Royal Holloway; University of London; London UK
| | | |
Collapse
|
22
|
van de Crommenacker J, Bourgeois YXC, Warren BH, Jackson H, Fleischer-Dogley F, Groombridge J, Bunbury N. Using molecular tools to guide management of invasive alien species: assessing the genetic impact of a recently introduced island bird population. DIVERS DISTRIB 2015. [DOI: 10.1111/ddi.12364] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Affiliation(s)
- J. van de Crommenacker
- Seychelles Islands Foundation; La Ciotat Building, Mont Fleuri, Mahé Victoria Seychelles
- Durrell Institute of Conservation and Ecology (DICE); School of Anthropology and Conservation; University of Kent; Marlowe Building Canterbury Kent UK
| | - Y. X. C. Bourgeois
- Zoologisches Institut, Evolutionsbiologie; University of Basel; Vesalgasse 1 4051 Basel Switzerland
| | - B. H. Warren
- Institute of Systematic Botany; University of Zurich; Zollikerstrasse 107 8008 Zurich Switzerland
| | - H. Jackson
- Durrell Institute of Conservation and Ecology (DICE); School of Anthropology and Conservation; University of Kent; Marlowe Building Canterbury Kent UK
| | - F. Fleischer-Dogley
- Seychelles Islands Foundation; La Ciotat Building, Mont Fleuri, Mahé Victoria Seychelles
| | - J. Groombridge
- Durrell Institute of Conservation and Ecology (DICE); School of Anthropology and Conservation; University of Kent; Marlowe Building Canterbury Kent UK
| | - N. Bunbury
- Seychelles Islands Foundation; La Ciotat Building, Mont Fleuri, Mahé Victoria Seychelles
| |
Collapse
|
23
|
Quirk M, Ponrartana S, Jackson H, Zeinati C. Pediatric thyroid nodules: role of the pediatric interventional radiologist and review of a pediatric specific entity. J Vasc Interv Radiol 2015. [DOI: 10.1016/j.jvir.2014.12.548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
24
|
Stewart TM, Plasencia M, Han H, Jackson H, Becker CB. Moderators and Predictors of Response to Eating Disorder Risk Factor Reduction Programs in Collegiate Female Athletes. Psychol Sport Exerc 2014; 15:713-720. [PMID: 25400505 PMCID: PMC4228963 DOI: 10.1016/j.psychsport.2014.02.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
OBJECTIVE The primary aim of this paper was to investigate moderators and predictors of response to two programs designed to reduce eating disorder risk factors in collegiate female athletes. This study served as an ancillary study to a parent trial that investigated the feasibility of an athlete modified cognitive dissonance-based program (AM-DBP) and an athlete modified healthy weight intervention program (AM-HWI). DESIGN 157 female collegiate athletes were randomized to either the AM-DBP or the AM-HWI program. Participants completed surveys at baseline, post-intervention, 6 weeks, and 1 year. METHODS After classifying sports as either lean or non-lean, we investigated if sport type acted as a moderator of program response to AM-DBP and AM-HWI using ANOVAs. Next, we examined whether baseline thin-ideal internalization, weight concern, shape concern, bulimic pathology, dietary restraint, and negative affect acted as predictors of changes in bulimic pathology using linear regression models. RESULTS Athletes in non-lean sports who received AM-DBP showed more improvement in negative affect versus non-lean sport athletes in AM-HWI. Higher baseline scores of bulimic pathology predicted greater response in bulimic pathology to both programs at 6-weeks. In contrast, athletes with higher dietary restraint and negative affect baseline scores showed decreased response to both interventions at 6-weeks. Finally, athletes with higher baseline shape concern showed a decreased response to the AM-HWI intervention at the post intervention time point. CONCLUSION Results from the present study indicate that lean/non-lean sport may not play a strong role in determining response to efficacious programs. Further, factors such as pre-existing bulimic pathology, dietary restraint, negative affect, and shape concern may affect general response to intervention versus specific responses to specific interventions.
Collapse
Affiliation(s)
- T M Stewart
- Pennington Biomedical Research Center, 6400 Perkins Rd., Baton Rouge, LA 70808
| | - M Plasencia
- Trinity University, One Trinity Place, San Antonio, TX 78212-2100
| | - H Han
- Pennington Biomedical Research Center, 6400 Perkins Rd., Baton Rouge, LA 70808
| | - H Jackson
- Trinity University, One Trinity Place, San Antonio, TX 78212-2100
| | - C B Becker
- Trinity University, One Trinity Place, San Antonio, TX 78212-2100
| |
Collapse
|
25
|
Krahn A, Jackson H, Macfarlane A, Wagner B, Tang A. A CANADIAN CARDIAC RATE BOOK: CARDIAC IMPLANTABLE ELECTRONIC DEVICE IMPLANTS (2006 to 2012). Can J Cardiol 2014. [DOI: 10.1016/j.cjca.2014.07.584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
26
|
Bennett M, Ayers D, Ding L, Jackson H, Krahn A. THERE IS NO DIFFERENCE IN LONGEVITY OF IMPLANTABLE CARDIOVERTER-DEfiBRILLATORS BETWEEN MANUFACTURERS. Can J Cardiol 2014. [DOI: 10.1016/j.cjca.2014.07.529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
27
|
Bennett M, Ayers D, Ding L, Jackson H, Krahn A. LONG-TERM SURVIVAL AFTER IMPLANTABLE CARDIOVERTER DEFIBRILLATOR IMPLANTATION: A POPULATION-BASED STUDY. Can J Cardiol 2014. [DOI: 10.1016/j.cjca.2014.07.603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
28
|
Huber GM, Blok HP, Butuceanu C, Gaskell D, Horn T, Mack DJ, Abbott D, Aniol K, Anklin H, Armstrong C, Arrington J, Assamagan K, Avery S, Baker OK, Barrett B, Beise EJ, Bochna C, Boeglin W, Brash EJ, Breuer H, Chang CC, Chant N, Christy ME, Dunne J, Eden T, Ent R, Fenker H, Gibson EF, Gilman R, Gustafsson K, Hinton W, Holt RJ, Jackson H, Jin S, Jones MK, Keppel CE, Kim PH, Kim W, King PM, Klein A, Koltenuk D, Kovaltchouk V, Liang M, Liu J, Lolos GJ, Lung A, Margaziotis DJ, Markowitz P, Matsumura A, McKee D, Meekins D, Mitchell J, Miyoshi T, Mkrtchyan H, Mueller B, Niculescu G, Niculescu I, Okayasu Y, Pentchev L, Perdrisat C, Pitz D, Potterveld D, Punjabi V, Qin LM, Reimer PE, Reinhold J, Roche J, Roos PG, Sarty A, Shin IK, Smith GR, Stepanyan S, Tang LG, Tadevosyan V, Tvaskis V, van der Meer RLJ, Vansyoc K, Van Westrum D, Vidakovic S, Volmer J, Vulcan W, Warren G, Wood SA, Xu C, Yan C, Zhao WX, Zheng X, Zihlmann B. Separated response function ratios in exclusive, forward π(±) electroproduction. Phys Rev Lett 2014; 112:182501. [PMID: 24856691 DOI: 10.1103/physrevlett.112.182501] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/24/2014] [Indexed: 06/03/2023]
Abstract
The study of exclusive π(±) electroproduction on the nucleon, including separation of the various structure functions, is of interest for a number of reasons. The ratio RL=σL(π-)/σL(π+) is sensitive to isoscalar contamination to the dominant isovector pion exchange amplitude, which is the basis for the determination of the charged pion form factor from electroproduction data. A change in the value of RT=σT(π-)/σT(π+) from unity at small -t, to 1/4 at large -t, would suggest a transition from coupling to a (virtual) pion to coupling to individual quarks. Furthermore, the mentioned ratios may show an earlier approach to perturbative QCD than the individual cross sections. We have performed the first complete separation of the four unpolarized electromagnetic structure functions above the dominant resonances in forward, exclusive π(±) electroproduction on the deuteron at central Q(2) values of 0.6, 1.0, 1.6 GeV(2) at W=1.95 GeV, and Q(2)=2.45 GeV(2) at W=2.22 GeV. Here, we present the L and T cross sections, with emphasis on RL and RT, and compare them with theoretical calculations. Results for the separated ratio RL indicate dominance of the pion-pole diagram at low -t, while results for RT are consistent with a transition between pion knockout and quark knockout mechanisms.
Collapse
Affiliation(s)
- G M Huber
- University of Regina, Regina, Saskatchewan S4S 0A2, Canada
| | - H P Blok
- VU university, NL-1081 HV Amsterdam, The Netherlands and NIKHEF, Postbus 41882, NL-1009 DB Amsterdam, The Netherlands
| | - C Butuceanu
- University of Regina, Regina, Saskatchewan S4S 0A2, Canada
| | - D Gaskell
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Horn
- Catholic University of America, Washington, DC 20064, USA
| | - D J Mack
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D Abbott
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - K Aniol
- California State University Los Angeles, Los Angeles, California 90032, USA
| | - H Anklin
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA and Florida International University, Miami, Florida 33119, USA
| | - C Armstrong
- College of William and Mary, Williamsburg, Virginia 23187, USA
| | - J Arrington
- Physics Division, Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - K Assamagan
- Hampton University, Hampton, Virginia 23668, USA
| | - S Avery
- Hampton University, Hampton, Virginia 23668, USA
| | - O K Baker
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA and Hampton University, Hampton, Virginia 23668, USA
| | - B Barrett
- Saint Mary's University, Halifax, Nova Scotia B3H 3C3 Canada
| | - E J Beise
- University of Maryland, College Park, Maryland 20742, USA
| | - C Bochna
- University of Illinois, Champaign, Illinois 61801, USA
| | - W Boeglin
- Florida International University, Miami, Florida 33119, USA
| | - E J Brash
- University of Regina, Regina, Saskatchewan S4S 0A2, Canada
| | - H Breuer
- University of Maryland, College Park, Maryland 20742, USA
| | - C C Chang
- University of Maryland, College Park, Maryland 20742, USA
| | - N Chant
- University of Maryland, College Park, Maryland 20742, USA
| | - M E Christy
- Hampton University, Hampton, Virginia 23668, USA
| | - J Dunne
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Eden
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA and Norfolk State University, Norfolk, Virginia 23504, USA
| | - R Ent
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - H Fenker
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - E F Gibson
- California State University, Sacramento, California 95819, USA
| | - R Gilman
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA and Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, USA
| | - K Gustafsson
- University of Maryland, College Park, Maryland 20742, USA
| | - W Hinton
- Hampton University, Hampton, Virginia 23668, USA
| | - R J Holt
- Physics Division, Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - H Jackson
- Physics Division, Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - S Jin
- Kyungpook National University, Daegu 702-701, Republic of Korea
| | - M K Jones
- College of William and Mary, Williamsburg, Virginia 23187, USA
| | - C E Keppel
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA and Hampton University, Hampton, Virginia 23668, USA
| | - P H Kim
- Kyungpook National University, Daegu 702-701, Republic of Korea
| | - W Kim
- Kyungpook National University, Daegu 702-701, Republic of Korea
| | - P M King
- University of Maryland, College Park, Maryland 20742, USA
| | - A Klein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - D Koltenuk
- University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | - V Kovaltchouk
- University of Regina, Regina, Saskatchewan S4S 0A2, Canada
| | - M Liang
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J Liu
- University of Maryland, College Park, Maryland 20742, USA
| | - G J Lolos
- University of Regina, Regina, Saskatchewan S4S 0A2, Canada
| | - A Lung
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D J Margaziotis
- California State University Los Angeles, Los Angeles, California 90032, USA
| | - P Markowitz
- Florida International University, Miami, Florida 33119, USA
| | | | - D McKee
- New Mexico State University, Las Cruces, New Mexico 88003-8001, USA
| | - D Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J Mitchell
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | | | - H Mkrtchyan
- A.I. Alikhanyan National Science Laboratory, Yerevan 0036, Armenia
| | - B Mueller
- Physics Division, Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - G Niculescu
- James Madison University, Harrisonburg, Virginia 22807, USA
| | - I Niculescu
- James Madison University, Harrisonburg, Virginia 22807, USA
| | | | - L Pentchev
- College of William and Mary, Williamsburg, Virginia 23187, USA
| | - C Perdrisat
- College of William and Mary, Williamsburg, Virginia 23187, USA
| | - D Pitz
- DAPNIA/SPhN, CEA/Saclay, F-91191 Gif-sur-Yvette, France
| | - D Potterveld
- Physics Division, Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - V Punjabi
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - L M Qin
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - P E Reimer
- Physics Division, Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - J Reinhold
- Florida International University, Miami, Florida 33119, USA
| | - J Roche
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P G Roos
- University of Maryland, College Park, Maryland 20742, USA
| | - A Sarty
- Saint Mary's University, Halifax, Nova Scotia B3H 3C3 Canada
| | - I K Shin
- Kyungpook National University, Daegu 702-701, Republic of Korea
| | - G R Smith
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Stepanyan
- A.I. Alikhanyan National Science Laboratory, Yerevan 0036, Armenia
| | - L G Tang
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA and Hampton University, Hampton, Virginia 23668, USA
| | - V Tadevosyan
- A.I. Alikhanyan National Science Laboratory, Yerevan 0036, Armenia
| | - V Tvaskis
- VU university, NL-1081 HV Amsterdam, The Netherlands and NIKHEF, Postbus 41882, NL-1009 DB Amsterdam, The Netherlands
| | | | - K Vansyoc
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - D Van Westrum
- University of Colorado, Boulder, Colorado 80309, USA
| | - S Vidakovic
- University of Regina, Regina, Saskatchewan S4S 0A2, Canada
| | - J Volmer
- VU university, NL-1081 HV Amsterdam, The Netherlands and DESY, Hamburg, Germany
| | - W Vulcan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - G Warren
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S A Wood
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C Xu
- University of Regina, Regina, Saskatchewan S4S 0A2, Canada
| | - C Yan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - W-X Zhao
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - X Zheng
- Physics Division, Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - B Zihlmann
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA and University of Virginia, Charlottesville, Virginia 22901, USA
| |
Collapse
|
29
|
Naylor HL, Jackson H, Walker GH, Macafee S, Magee K, Hooper L, Stewart L, MacLaughlin HL. British Dietetic Association evidence-based guidelines for the protein requirements of adults undergoing maintenance haemodialysis or peritoneal dialysis. J Hum Nutr Diet 2013; 26:315-28. [PMID: 23731266 DOI: 10.1111/jhn.12052] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Existing nutritional guidelines suggest that protein requirements of adults with stage five chronic kidney disease undergoing haemodialysis (HD) or peritoneal dialysis (PD) are increased as a result of protein losses during dialysis. The present review aimed to update previous guidance and develop evidence-based practice guidelines on the protein requirements of adults undergoing maintenance dialysis. METHODS Following a PICO approach (Participants or Population, Intervention or Exposure, Comparison and Outcome), four research questions were formulated to investigate the total protein requirement and protein quality required by adults undergoing HD and PD. A comprehensive, systematic review was undertaken using the databases Medline, EMBASE and the Cochrane Library from 2005 to September 2009 for HD studies and from 1997 to September 2009 for PD studies. RESULTS The literature search yielded 2931 studies, which were assessed for inclusion. Following appraisal, 19 studies in HD and 18 studies in PD met the inclusion criteria and were systematically reviewed. Limited good quality evidence supports the recommendations that: (i) adults undergoing maintenance HD require a minimum protein intake of 1.1 g kg(-1) ideal body weight (IBW) per day; and (ii) adults undergoing maintenance PD require a minimum protein intake of 1.0-1.2 kg(-1) IBW per day, in conjunction with an adequate energy intake. There were no studies that addressed the quality of protein for either HD or PD. CONCLUSIONS Evidence suggests that nutritional status may be maintained with lower protein intakes than previously recommended. However, the evidence base is limited and further randomised controlled trials are required to establish the optimal protein intake for dialysis patients.
Collapse
Affiliation(s)
- H L Naylor
- Betsi Cadwaladr University Health Board, Bangor, UK.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Fisher K, Paxton R, Jackson H, Noble S, Thomsett K, Reynolds S, Hart K, Engel B. Comparison of screening tools in patients undergoing haemodialysis. J Hum Nutr Diet 2011. [DOI: 10.1111/j.1365-277x.2011.01175_8.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
31
|
Matthay KK, Weiss BD, Villablanca J, Maris JM, Yanik GA, Groshen SG, Jackson H, Hawkins R, Goodarzian F, Panigrahy A, DuBois SG, Stubbs J, Towbin A, Barrett JA, LaFrance ND, Babich JW. Dosimetry, toxicity, and response in a phase IIa trial of no-carrier added iobenguane I-131 (nca-MIBG): A New Approach to Neuroblastoma Therapy (NANT) study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.9512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
32
|
Kelly PJ, Baker GA, van den Broek MD, Jackson H, Humphries G. The detection of malingering in memory performance: The sensitivity and specificity of four measures in a UK population. British Journal of Clinical Psychology 2011; 44:333-41. [PMID: 16252435 DOI: 10.1348/014466505x35687] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVES To investigate the validity of a clinical neuropsychological battery for the detection of malingering on tests of memory. METHODS A simulated scenario design was developed to investigate the effectiveness of a battery of four neuropsychological tests in the detection of malingering; the Coin in the Hand Test (CIH), Autobiographical Memory Index (AMI), Rey I 5-Item Test (RIT),and the Wechsler Mental Control Test (MCT). The performances of patients with an acquired brain injury (N = 40) were compared with two groups of controls instructed either to simulate a head injury performance (N = 40) or do their best (N = 40). RESULTS The CIH and MCT demonstrated good validity and displayed high sensitivity and specificity. The RIT and the AMI was relatively poor in distinguishing between simulators and patients. CONCLUSIONS The sensitivity and specificity of all four tests to the detection of malingering has been assessed. Two of the tests the CIH and MCT would be useful as a quick and accurate screening tool for detecting malingering.
Collapse
Affiliation(s)
- P J Kelly
- Neurological Sciences, Clinical Science Center for Research and Education, Liverpool, UK
| | | | | | | | | |
Collapse
|
33
|
Jackson H, Parker F, Glover EC. STUDIES OF DISEASES OF THE LYMPHOID AND MYELOID TISSUES. I : THE CHEMICAL METABOLISM OF NORMAL AND PATHOLOGICAL LYMPH NODES. ACTA ACUST UNITED AC 2010; 52:547-60. [PMID: 19869787 PMCID: PMC2131896 DOI: 10.1084/jem.52.4.547] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
From a study of the metabolism of 71 lymph nodes and tumors one may conclude: 1. The nature of a tumor can not be predicted from the metabolism because too much overlapping of metabolic rates exists between the pathological groups. 2. There is no evidence metabolically one way or another as to whether malignant lymphomata of any type should be classed as neoplastic or as infectious processes. 3. The degree of cell differentiation can in most cases be foretold by the percentage difference between the aerobic and the anaerobic glycolysis. The greater the differentiation the greater the percentage difference. Sarcomata in general constitute an exception to this rule. 4. The degree of malignancy in carcinoma, but not in other tumors, can, with certain exceptions, be predicted from the height of the value U. 5. Human sarcomata appear to have a metabolism far more closely comparable to that of benign tumors than to that of carcinomata. They do not behave as malignant tumors under the Warburg classification. Their energy requirements are not of the same order as those of carcinoma. 6. One can not from the value U or from the glycolytic rates predict whether or not a tissue should be classed as neoplastic. 7. Warburg's findings for carcinomata are confirmed and amplified.
Collapse
Affiliation(s)
- H Jackson
- Thorndike Memorial and Pathological Laboratories, Boston City Hospital, the Medical Service, Collis P. Huntington Memorial Hospital, and the Department of Medicine, Harvard University, Boston
| | | | | | | |
Collapse
|
34
|
Rossit S, Muir K, Reeves I, Duncan G, Livingstone K, Jackson H, Castle P, Harvey M. Non-lateralized impairments in anti- but not pro-pointing in patients with hemispatial neglect. J Vis 2010. [DOI: 10.1167/8.6.50] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
35
|
Harvey M, Muir K, Reeves I, Duncan G, Livingstone K, Jackson H, Castle P, Rossit S. Pointing and bisection in open and closed loop reaching in patients with hemispatial neglect. J Vis 2010. [DOI: 10.1167/8.6.305] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
36
|
Robinson J, Harris MG, Harrigan SM, Henry LP, Farrelly S, Prosser A, Schwartz O, Jackson H, McGorry PD. Suicide attempt in first-episode psychosis: a 7.4 year follow-up study. Schizophr Res 2010; 116:1-8. [PMID: 19864115 DOI: 10.1016/j.schres.2009.10.009] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2009] [Revised: 10/05/2009] [Accepted: 10/10/2009] [Indexed: 11/18/2022]
Abstract
BACKGROUND Individuals with first-episode psychosis demonstrate high rates of suicide attempt (SA). AIMS 1) To examine the prevalence of, and risk factors for, SA in a first-episode psychosis (FEP) cohort over a 7.4 year follow-up period. 2) To investigate differences between single versus multiple suicide attempters. METHODS This study reports baseline and follow-up data from a naturalistic, prospective follow-up of 413 FEP patients treated at a specialist early psychosis centre. Assessments were conducted at treatment entry, initial symptom remission or stabilization, and long term follow-up. Binary logistic regression models were used to assess unadjusted and adjusted associations between early illness and sociodemographic characteristics and two outcome measures: any SA during follow-up; and multiple SAs. RESULTS Follow-up data were available for 282 participants. Sixty-one (21.6%) made a suicide attempt over the follow-up period, including 12 successful suicides. The following baseline risk factors increased the risk of any SA: history of self-harm (OR=4.27; p<0.001), suicidal tendencies (OR=2.30; p=0.022), being depressed for >50% of the initial psychotic episode (OR=2.49; p=0.045), and hopelessness (OR=2.03; p=0.030). History of problem alcohol use increased the risk of multiple SAs (OR=4.43; 95% CI (1.05-18.7); p=0.043). DISCUSSION The prevalence of suicide attempt in this study exceeds reports from short-term FEP studies but is comparable to longer term follow-up studies, indicating that risk remains elevated for at least 7 years following commencement of treatment. The key predictor of future suicide attempt was previous self-harm, indicating that interventions for self-harm are required.
Collapse
Affiliation(s)
- J Robinson
- Orygen Youth Health and Research Centre, Early Psychosis Prevention and Intervention Centre (EPPIC), Parkville Victoria 3052, Melbourne, Australia.
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Affiliation(s)
- A Craft
- Royal Victoria Infirmary, Newcastle Upon Type NE1 4LP, UK.
| | | |
Collapse
|
38
|
|
39
|
Rooney FR, Jackson H. Antifertility activity of alkyl esters of nitro- and acetamido-benzenesulphonic acids. Andrologia 2009; 6:263-8. [PMID: 4440884 DOI: 10.1111/j.1439-0272.1974.tb01213.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
|
40
|
Rossit S, Malhotra P, Muir K, Reeves I, Duncan G, Livingstone K, Jackson H, Hogg C, Castle P, Learmonth G, Harvey M. No Neglect-Specific Deficits in Reaching Tasks. Cereb Cortex 2009; 19:2616-24. [DOI: 10.1093/cercor/bhp016] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Pang G, Andrews W, Clarkson C, Dwyer J, Holyday M, Jackson H, Kepreotes H, Lambert K, Paton M, Robertson K, Scott B, Stradling E, Talbot P, Wagner S, Ward K. Home enteral nutrition patients in NSW: Results from a one month audit of new and existing HEN patients from NSW public healthcare facilities. Nutrition 2008. [DOI: 10.1016/j.nut.2008.01.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
42
|
Pang G, Andrews W, Clarkson C, Dwyer J, Holyday M, Jackson H, Kepreotes H, Lambert K, Paton M, Robertson K, Scott B, Stradling E, Talbot P, Wagner S, Ward K. Establishing a NSW HEN registry. Nutrition 2008. [DOI: 10.1016/j.nut.2008.01.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
43
|
Williams N, Bertoncello I, Jackson H, Arnold J, Kavnoudias H. The role of interleukin 6 in megakaryocyte formation, megakaryocyte development and platelet production. Ciba Found Symp 2007; 167:160-70; discussion 170-3. [PMID: 1425011 DOI: 10.1002/9780470514269.ch10] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Megakaryocytopoiesis is the cellular amplification and differentiation of precursors into immature megakaryocytes, and the cytoplasmic maturation of these megakaryocytes, a process terminating in the release of platelets into the circulation. Interleukin 6 (IL-6) stimulates megakaryocytopoiesis in the bone marrow, increasing platelet numbers in the circulation. IL-6 alone is poorly active on the growth of stem cell populations, but acts in synergy with stem cell factor (c-kit ligand) to expand the committed myeloid progenitor compartments but not the megakaryocyte progenitors. IL-6 has a direct action on megakaryocyte progenitors but only in synergy with low doses of interleukin 3 (IL-3), increasing the number of immature megakaryocytes and enhancing the processes of development into mature megakaryocytes. IL-6 is about 10 times more active on megakaryocytes than on megakaryocyte progenitors in cell culture. It is active alone and will stimulate increases in cell size and DNA content. IL-6 does not appear to stimulate the process of platelet release. IL-6 is found in bone marrow, in both macrophage subsets and megakaryocytes, indicating that it may be an important physiological regulator of both paracrinal (microenvironmental) and autocrinal mechanisms controlling megakaryocyte development in bone marrow.
Collapse
Affiliation(s)
- N Williams
- Department of Physiology, University of Melbourne, Parkville, Victoria, Australia
| | | | | | | | | |
Collapse
|
44
|
Jackson H, Dickerson D, Gunther A. THE REDUCTION OF INTRACRANIAL PRESSURE IN CEREBRAL INJURY BY THE INTRAVENOUS USE OF HYPERTONIC SUCROSE SOLUTION. Ann Surg 2007; 106:161-8. [PMID: 17857026 PMCID: PMC1390491 DOI: 10.1097/00000658-193708000-00001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
45
|
Farrelly S, Harris MG, Henry LP, Purcell R, Prosser A, Schwartz O, Jackson H, McGorry PD. Prevalence and correlates of comorbidity 8 years after a first psychotic episode. Acta Psychiatr Scand 2007; 116:62-70. [PMID: 17559602 DOI: 10.1111/j.1600-0447.2006.00922.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE While rates and correlates of comorbidity have been investigated in the early course of psychosis, little is known about comorbidity in the medium-to-longer term or its relationship with outcome. METHOD A total of 182 first-episode psychosis (FEP) patients who met DSM-IV criteria for a current psychotic disorder 8 years after index presentation were grouped according to concurrent comorbidity [no concurrent axis I disorder; concurrent substance use disorder (SUD); other concurrent axis I disorder; concurrent SUD and other axis I disorder]. Outcomes were compared between groups controlling for relevant covariates. RESULTS As much as 39% met criteria for one or more concurrent axis 1 diagnoses. Comorbidity was associated with greater severity of general psychopathology, but not with measures of functioning, treatment or negative symptoms. CONCLUSION Specific combinations of comorbid disorders may influence patterns of psychotic symptomatology. Routine examination of axis I disorders is warranted in the ongoing management of psychosis.
Collapse
Affiliation(s)
- S Farrelly
- ORYGEN Research Centre & Department of Psychiatry, The University of Melbourne, Parkville, Melbourne, Victoria, Australia
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Jackson H, McAuliffe CA, Perera A, Sharma HL, Tinker NJ. An improved synthetic procedure for the preparation of 195mPt labelled anti-tumour complexes. J Labelled Comp Radiopharm 2006. [DOI: 10.1002/jlcr.2580291004] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
47
|
Abstract
Photodynamic therapy (PDT) is a new evidence-based treatment modality available for choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD). Eligibility for PDT is based on the morphological classification of the neovascular complex, the benefit being greater in classic with no occult lesions. Lesion size is also shown to be a predictive factor for treatment benefit. This retrospective case series looked at effect of initial and final lesion size on the visual outcome of patients with subfoveal classic with no occult CNV and found that increasing initial and final lesion size is associated with poorer visual outcome.
Collapse
Affiliation(s)
- S Sivaprasad
- West Kent Eye Centre, Princess Royal University Hospital, Orpington, Kent BR6 8ND, UK.
| | | | | |
Collapse
|
48
|
Affiliation(s)
- H Jackson
- The Department of Physiology, the University of Manchester
| |
Collapse
|
49
|
Heilbron IM, Jackson H, Jones RN. The lipochromes of sea anemones: Carotenoid pigments of Actinia equina, Anemonia sulcata, Actinoloba dianthus and Tealia felina. Biochem J 2006; 29:1384-8. [PMID: 16745804 PMCID: PMC1266640 DOI: 10.1042/bj0291384] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- I M Heilbron
- The Department of Chemistry, University of Manchester
| | | | | |
Collapse
|
50
|
Affiliation(s)
- H Jackson
- Department of Physiology, University of Manchester
| | | |
Collapse
|